Literature DB >> 6831995

Effects of exogenous glucagon on pancreatic and biliary ductal and sphincteric pressures in man demonstrated by endoscopic manometry and correlation with plasma glucagon.

D L Carr-Locke, J A Gregg, T T Aoki.   

Abstract

An endoscopic manometric technique was used to investigate the effects of glucagon on pancreatic duct, common bile duct, pancreatic duct sphincter, and bile duct sphincter pressures in 20 healthy volunteers. Glucagon was given by intravenous infusion at rates of 0.016, 0.0625, 0.25, 1.0, 4.0, and 16.0 micrograms/kg/hr and also as an intravenous bolus of 1 mg. Plasma glucagon was measured by radioimmunoassay. Glucagon significantly reduced peak bile duct sphincter pressure from 49.1 +/- 3.7 mm Hg (mean +/- SD) to 37.8 +/- 2.9 mm Hg (P less than 0.01) at a rate of 0.016 microgram/kg/hr, reaching a maximum effect at rates of 0.25 microgram/kg/hr and above. Reduction in pancreatic duct sphincter, pancreatic duct, and bile duct pressures; slowing of sphincter wave frequency; and shortening of wave duration occurred at infusion rates of 1.0 microgram/kg/hr or greater when plasma concentrations were supraphysiological. We conclude that glucagon has a physiological action on the bile duct sphincter but that all other effects on this area are pharmacological.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831995     DOI: 10.1007/bf01324947

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

Review 1.  Actions of gastrointestinal hormones and related peptides on the motor function of the biliary tract.

Authors:  T M Lin
Journal:  Gastroenterology       Date:  1975-10       Impact factor: 22.682

2.  Hormone-fuel concentrations in anephric subjects. Effect of hemodialysis (with special reference to amino acids).

Authors:  O P Ganda; T T Aoki; J S Soeldner; R S Morrison; G F Cahill
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

Review 3.  Glucagon physiology in health and disease.

Authors:  R Sherwin; P Felig
Journal:  Int Rev Physiol       Date:  1977

Review 4.  ERCP.

Authors:  P B Cotton
Journal:  Gut       Date:  1977-04       Impact factor: 23.059

5.  Glucagon radioimmunoassay using antiserum 30K: interference by plasma.

Authors:  G C Weir; R C Turner; D B Martin
Journal:  Horm Metab Res       Date:  1973-07       Impact factor: 2.936

6.  Inhibition of meal-stimulated gastric acid secretion in man by exogenous and endogenous pancreatic glucagon.

Authors:  F B Loud; D Froberg; J Reichardt; J J Holst; J F Rehfeld; J Christiansen
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

7.  Glucagon inhibition of secretin and combined secretin and cholecystokinin stimulated pancreatic exocrine secretion in health and disease.

Authors:  J E Clain; G O Barbezat; M M Waterworth; S Bank
Journal:  Digestion       Date:  1978       Impact factor: 3.216

8.  Studies of pancreatic alpha cell function in normal and diabetic subjects.

Authors:  R H Unger; E Aguilar-Parada; W A Müller; A M Eisentraut
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

9.  Effects of exogenous secretin on pancreatic and biliary ductal and sphincteric pressures in man demonstrated by endoscopic manometry and correlation with plasma secretin levels.

Authors:  D L Carr-Locke; J A Gregg; W Y Chey
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

10.  Endoscopic manometry of pancreatic and biliary sphincter zones in man. Basal results in healthy volunteers.

Authors:  D L Carr-Locke; J A Gregg
Journal:  Dig Dis Sci       Date:  1981-01       Impact factor: 3.199

View more
  7 in total

1.  Effect of intravenous glucagon and glucagon-(1-21)-peptide on motor activity of sphincter of Oddi in humans.

Authors:  J Ponce; V Garrigues; V Pertejo; T Sala; M J Lazaro; A De Val; J Picazo
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

2.  Glucagon-(1-21)-peptide. Study of its action on sphincter of Oddi function by endoscopic manometry.

Authors:  J F Rey; M Greff; J Picazo
Journal:  Dig Dis Sci       Date:  1986-04       Impact factor: 3.199

Review 3.  Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A "Scoping" Literature Review.

Authors:  Kemmian D Johnson; Abhilash Perisetti; Benjamin Tharian; Ragesh Thandassery; Priya Jamidar; Hemant Goyal; Sumant Inamdar
Journal:  Dig Dis Sci       Date:  2019-12-02       Impact factor: 3.199

4.  Does topical GTN on the sphincter of Oddi facilitate ERCP? A double-blind randomized control trial.

Authors:  A Talwar; C Dare; J Pain
Journal:  Surg Endosc       Date:  2005-05-04       Impact factor: 4.584

5.  Endoscopic pancreatic and biliary manometry in pancreatic, biliary, and papillary disease, and after endoscopic sphincterotomy and surgical sphincteroplasty.

Authors:  J A Gregg; D L Carr-Locke
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

6.  Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment.

Authors:  Murat Pekgöz
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

7.  Clinical safety and outcomes of glucagon use during endoscopic retrograde cholangiopancreatography (ERCP).

Authors:  Abhilash Perisetti; Hemant Goyal; Neil Sharma
Journal:  Endosc Int Open       Date:  2022-04-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.